PT-141 (bremelanotide): who it's approved for, what it does, and what it costs

Here's the short version. PT-141 is a real, FDA-approved drug, but for a narrow group: premenopausal women whose low desire is new, constant and distressing ^[2]. A compounded PT-141 preparation does not inherit Vyleesi’s approval or clinical evidence. If libido is your goal, this page tells you what the trials found, what it can cost and what to ask first. For the bigger picture on hormones and desire, start at the hormones shortlist.

PT-141 works in the brain, not the blood vessels

Bremelanotide is a melanocortin receptor agonist. The label says the mechanism by which it improves HSDD is unknown. Receptor activity should not be treated as a complete explanation of an individual benefit ^[2].

The name PT-141 is its old research code. Vyleesi is the brand, made today by Cosette Pharmaceuticals. The approved form is a single-dose autoinjector that holds 1.75 mg in 0.3 mL ^[2].

The label covers one specific kind of low desire

The label is precise, and the details matter. It's for low sexual desire that causes marked distress or relationship difficulty and isn't explained by something else ^[2].

VYLEESI is not indicated for the treatment of HSDD in postmenopausal women or in men. VYLEESI is not indicated to enhance sexual performance.^[2]

• Acquired means desire used to be fine and then dropped.
• Generalized means it's low regardless of partner, setting or type of stimulation.
• It must not come from another medical or mental health condition, relationship problems, or a medication.

That last point is why a good visit asks about antidepressants, birth control, thyroid problems and stress. If one of those explains the drop, the label doesn't fit.

Desire scores rose a little; side effects were common

Two identical 24-week trials, called RECONNECT, randomized 1,267 premenopausal women with HSDD ^[4]. The safety population included 1,247 women and the modified-intent-to-treat efficacy population 1,202; these denominators differ from total randomization. The trials measured changes on two questionnaires: one for desire, one for distress about low desire.

The placebo-adjusted desire and distress changes were statistically significant, but a scale change is not the same outcome as more satisfying sexual events. The label reports no significant treatment difference for that secondary endpoint ^[2]. Discuss the outcome that matters to you rather than treating a positive questionnaire score as a promise of every sexual-function benefit.

Participation in an open-label extension is not a direct randomized measure of preference or the reason someone stopped. The label’s adverse-reaction discontinuation figures are the clearer measure for that specific tolerability question ^[2].

It also helps to know who was in the trials. Women averaged 39 years old, 85.6% were white and 96.6% came from US sites ^[4]. The label's trial summary gives an age range of 19 to 56 ^[2]. Results may not carry over to groups the trials barely included, and those pivotal trials do not establish effectiveness in postmenopausal women.

Nausea hits 4 in 10, and blood pressure rises after each dose

For men, it's off-label with no phase 3 trial

Many men's programs sell PT-141. Vyleesi is not indicated for men, and its pivotal phase 3 trials enrolled premenopausal women ^[4]. That is an indication limit, not the same as a contraindication. A clinician may consider an approved product off label, while FDA has not established safety and effectiveness for that use. A compounded preparation has separate requirements and is not simply the approved product used off label.

Low desire has multiple possible causes; evaluation should not presume testosterone deficiency or a need for hormone treatment. Our testosterone guide explains when treatment is on-label. For women around menopause, the HRT guide covers a different set of options, since Vyleesi isn't approved after menopause.

Brand Vyleesi and compounded PT-141 aren't the same product

Same active ingredient, different paths. Vyleesi is a factory-made autoinjector reviewed by FDA. Compounded bremelanotide is mixed by a pharmacy for each patient, and FDA doesn't review those products before they're dispensed. Strength, form and quality checks depend on the pharmacy. The full comparison, including what to ask about the pharmacy, is in PT-141 or Vyleesi.

If you're offered a compounded product, these questions are worth asking before you pay:

• Which pharmacy makes it, and is it a licensed 503A pharmacy or a registered outsourcing facility?
• Is it an injection, a nasal spray or something else? Vyleesi's trials tested the injection.
• What strength is it, and how does that compare with the label's 1.75 mg autoinjector?
• Can the program prescribe brand Vyleesi instead if you'd rather have the FDA-reviewed product?

What online PT-141 programs charge a month

A current AgelessRx product offer explicitly separates a first-month discount from its ongoing monthly amount. That is a compounded preparation; it should not be compared as if it were the approved Vyleesi autoinjector or a standard price for all formulations.

Two things move the bill. Longer prepaid plans lower the monthly figure but take the money up front. Some providers also charge for the visit or a membership. Ask for the month-two total in writing before you enter a card. The cost guides explain how to compare plans fairly.

Whether it's worth trying depends on what you can tolerate

The pivotal trials improved desire and distress measures in the labeled population. The safety review reports 70% of the drug group versus 87% of placebo participants proceeded to an open-label phase, but that is not proof of preference or an individual benefit. Nausea was a common reason for treatment discontinuation ^[5].

The decision concerns the exact symptom, labeled eligibility, contraindications, other medicines and the treatment’s benefits and harms. Controlled blood pressure alone does not establish suitability. Men, postmenopausal women and people seeking performance enhancement fall outside the approved indication; discuss that evidence gap rather than assuming a compounded product resolves it.

Getting it prescribed takes a short medical visit

Online, the usual path is an intake form and a clinician review, sometimes by video. Expect questions about blood pressure, heart disease, pregnancy plans and medicines you take. Those come straight from the label's warnings.

1. Say what changed and when. The label fits new, constant low desire, not a dip with one partner.
2. Share your blood pressure readings and heart history.
3. List every medicine, especially naltrexone, antibiotics and antidepressants.
4. Ask whether the program prescribes brand Vyleesi or a compounded product, and which pharmacy makes it.

Not sure PT-141 is even the right fit? The 30-second match sorts libido, hormone and energy goals into a short list.